Neuropace, Inc.
NPCENeuropace is a medical technology company that develops and commercializes the RNS System, the first brain-responsive neuromodulation system for treating drug-resistant epilepsy.
Earnings
Next report
Nov 3, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Neuropace is a medical technology company that develops and commercializes the RNS System, the first brain-responsive neuromodulation system for treating drug-resistant epilepsy. The system utilizes a closed-loop technology that monitors brain activity in real-time, detects patient-specific abnormal electrical patterns, and delivers targeted electrical pulses to prevent seizures. By combining personalized therapy with continuous data collection, the company provides clinicians with insights for remote patient monitoring and optimized treatment decisions.
Neuropace holds a unique position as the provider of the only commercially available closed-loop, brain-responsive neuromodulation system that records continuous iEEG data.
FAQ
- What is Neuropace, Inc.'s market cap?
- Neuropace, Inc. (NPCE) has a market capitalization of $484.0M and trades on NASDAQ.
- What is Neuropace, Inc.'s revenue and profitability?
- Neuropace, Inc. generated $98.8M in trailing twelve-month revenue with a net loss of $19.1M, representing a net margin of -19.3%. Gross margin stands at 79.6%, with free cash flow of -$12.0M. The latest reported period is Q2 2026.
- Who are Neuropace, Inc.'s competitors?
- Neuropace, Inc.'s key competitors include LivaNova, Medtronic, Neuraxis, Inc., and others. These companies compete in similar markets and product categories.
- Where is Neuropace, Inc. headquartered?
- Neuropace, Inc. is headquartered in United States of America and employs approximately 181 people. It has been publicly traded since 2021.
